Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) FCF Margin (2016 - 2025)

Sangamo Therapeutics has reported FCF Margin over the past 16 years, most recently at 171.42% for Q4 2025.

  • Quarterly results put FCF Margin at 171.42% for Q4 2025, down 12222.0% from a year ago — trailing twelve months through Dec 2025 was 245.96% (down 12724.0% YoY), and the annual figure for FY2025 was 245.96%, down 12939.0%.
  • FCF Margin for Q4 2025 was 171.42% at Sangamo Therapeutics, up from 4902.75% in the prior quarter.
  • Over the last five years, FCF Margin for SGMO hit a ceiling of 23.89% in Q3 2024 and a floor of 10212.68% in Q1 2024.
  • Median FCF Margin over the past 5 years was 232.59% (2021), compared with a mean of 1507.76%.
  • Biggest five-year swings in FCF Margin: crashed -1016425bps in 2024 and later surged 980282bps in 2025.
  • Sangamo Therapeutics' FCF Margin stood at 157.05% in 2021, then plummeted by -71bps to 269.16% in 2022, then tumbled by -777bps to 2361.8% in 2023, then soared by 98bps to 49.2% in 2024, then tumbled by -248bps to 171.42% in 2025.
  • The last three reported values for FCF Margin were 171.42% (Q4 2025), 4902.75% (Q3 2025), and 98.46% (Q2 2025) per Business Quant data.